The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Yang, P ^a   Du, C W ^a   Kwan, M ^b   Liang, S X ^a   Zhang, G J ^a,c  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VISCERA;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; VISCERA;

EID: 84880876654     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02246     Document Type: Article

References (38)

1. Largillier, R. et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19 (12), 2012 (2008).
2. Nakopoulou, L. L. et al. Prognostic significance of the co-expression of p53 and cerbB- 2 proteins in breast cancer. J Pathol 179 (1), 31 (1996).
3. Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266 (5186), 807 (1994).
4. Yamashita, H. et al. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8 (4), R48 (2006).
5. Rolland, P. et al. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 120 (6), 1311 (2007).
6. Andersson, J. et al.Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 16 (5), 743 (2005).
7. Dai, M. S., Sun, X. X. & Lu, H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 28 (13), 4365 (2008).
8. Alsner, J. et al. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6 (10), 3923 (2000).
9. Dookeran, K. A. et al. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol 17 (5), 1398 (2010).
10. Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (33), 5287 (2007).
11. Wiltschke, C. et al. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 120 (12), 737 (1994).
12. Daidone, M. G. et al. p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelialstromal tumours. Eur J Cancer 32A (8), 1388 (1996).
13. Rosen, P. P. et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13 (4), 821 (1995).
14. Elledge, R. M. et al. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54 (14), 3752 (1994).
15. Kroger, N. et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12 (1), 159 (2006).
16. Gulben, K., Berberoglu, U., Cengiz, A. & Altinyollar, H. Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer. World J Surg 31 (9), 1724 (2007).
17. Linjawi, A. et al. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 198 (1), 83 (2004).
18. Overgaard, J. et al. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 39 (3), 327 (2000).
19. Clegg, H. V., Itahana, K. & Zhang, Y. Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle 7 (3), 287 (2008).
20. Gao, Q. Z. et al. [Significance and expression of p53, p21(Cip1/WAF1) and Gadd45alpha in breast neoplasm tissues]. Zhonghua Yi Xue Za Zhi 92 (34), 2389 (2012).
21. Sawaki, M. et al. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 13 (2), 172 (2006).
22. Wedin, R., Skoog, L. & Bauer, H. C. Proliferation rate, hormone receptor status and p53 expression in skeletal metastasis of breast carcinoma. Acta Oncol 43 (5), 460 (2004).
23. Domagala, W. et al. p53 protein and vimentin in invasive ductal NOS breast carcinoma - relationship with survival and sites of metastases. Eur J Cancer 30A (10), 1527 (1994).
24. Chang, J. et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97 (3), 545 (2003).
25. Borresen-Dale, A. L. TP53 and breast cancer. Hum Mutat 21 (3), 292 (2003).
26. Varna, M. et al. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol 2011, 284584 (2011).
27. Lacroix, M., Toillon, R. A. & Leclercq, G. p53 and breast cancer, an update. Endocr Relat Cancer 13 (2), 293 (2006).
28. Rahko, E. et al. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 39 (4), 447 (2003).
29. Shapira, I., Lee, A., Vora, R. & Budman, D. R. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. Crit Rev Oncol Hematol (2013).
30. Muller, P. A. et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 139 (7), 1327 (2009).
31. Brosh, R. & Rotter, V. When mutants gain new powers: news from themutant p53 field. Nat Rev Cancer 9 (10), 701 (2009).
32. Petitjean, A. et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (15), 2157 (2007).
33. Lowe, S. W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266 (5186), 807 (1994).
34. Yamashita, H. et al. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8 (4), R48 (2006).
35. Lowe, S. W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266 (5186), 807 (1994).
36. Wedin, R., Skoog, L. & Bauer, H. C. Proliferation rate, hormone receptor status and p53 expression in skeletal metastasis of breast carcinoma. Acta Oncol 43 (5), 460 (2004).
37. Zhu, H. B. et al. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol 11, 22 (2013).
38. Lara, J. F. et al. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res 17 (15), 5170 (2011).